난소암 시장 보고서 : 유형, 치료법, 최종사용자, 지역별(2026-2034년)

The global ovarian cancer market size reached USD 2.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.8 Billion by 2034, exhibiting a growth rate (CAGR) of 9.21% during 2026-2034. North America leads the market attributed to its advanced healthcare infrastructure, strong research capabilities, and high demand for innovative treatment options. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and female hormones. It typically develops when abnormal cells in the ovaries grow and multiply uncontrollably, forming a tumor. There are different types of ovarian cancer, and they can be classified based on the specific cells from which they originate. The most common type is epithelial ovarian cancer, which arises from the surface of the ovary. Other less common types include germ cell tumors and stromal tumors, which develop from the cells that produce eggs and hormones, respectively. Common symptoms of ovarian cancer include abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, frequent urination, and changes in bowel habits.

The development of targeted treatments, immune therapies, and individualized medicine is broadening therapeutic choices. These therapies are more efficient and less harmful than conventional chemotherapy, enhancing patient results. Moreover, advancements in clinical trials are fostering innovation, encouraging new treatments that provide optimism for improved survival rates and enhanced quality of life for patients. Besides this, collaborative partnerships among pharmaceutical firms, research organizations, and non-profit entities are driving advancements in ovarian cancer therapies. These collaborations improve drug development, clinical trials, and awareness initiatives by combining resources and expertise. Teamwork accelerates the translation of research into effective treatments and enhances the overall market outlook for ovarian cancer treatment. Furthermore, the growing awareness about ovarian cancer is leading to earlier diagnosis, which is essential for enhancing survival rates. Health campaigns and advocacy organizations are informing individuals about symptoms and risk elements, encouraging more women to pursue medical consultation. Timely detection via enhanced screening methods boosts the efficacy of current therapies.

OVARIAN CANCER MARKET TRENDS:

Increased Healthcare Investments and Government Initiatives

Governments around the globe, are becoming more aware about the increasing impact of cancer, are directing additional resources towards research, treatment initiatives, and the advancement of innovative medical technologies. These investments facilitate the discovery of novel therapeutic strategies, improved diagnostic instruments, and refined treatment methodologies for ovarian cancer. In addition, partnerships among pharmaceutical companies, biotech organizations, and academic institutions are speeding up the identification of new treatments. These collaborations result in the creation of more focused, individualized, and efficient treatment alternatives. Apart from this, the heightened financial backing promotes the growth of clinical trials and the swift commercialization of innovative therapies. This collaborative endeavor boosts patient care, increases survival rates, and guarantees that additional resources are accessible for ongoing research, ultimately contributing to the growth of the ovarian cancer market and enhancing patient outcomes.

Approval of Targeted Therapies and New Treatment Standards

The introduction of targeted therapies and the creation of new treatment benchmarks for particular ovarian cancer subtypes are bolstering the market growth. Progress in comprehending the genetic and molecular foundations of ovarian cancer is resulting in the creation of therapies that focus on particular mutations, providing patients with more effective treatment choices. With new therapies showing encouraging effectiveness in clinical trials and receiving regulatory approval, they offer more tailored and accurate care, enhancing patient outcomes. This advancement in targeted therapies is increasing survival rates while also generating higher demand for specialized treatments, driving further growth and investment in the ovarian cancer industry. In May 2025, the FDA approved Verastem Oncology's drug combination for low-grade serous ovarian cancer (LGSOC) driven by KRAS mutations, marking the first treatment for this rare cancer. The combination of avutometinib and defactinib showed a 44% response rate in a Phase 2 study. This approval sets the therapy as the new standard of care for recurrent LGSOC with KRAS mutations.

Advancements in Research and Treatment Options

The continuous advancement of innovative therapies is significantly driving the growth of the ovarian cancer market by improving treatment efficacy and patient outcomes. Advances in targeted treatments, immunotherapy, and personalized medicine offer patients more customized and effective options for therapy. These developments enhance survival rates and treatment effectiveness, contributing to the market growth. Besides this, studies on biomarkers and genetic profiling are resulting in more targeted and timely treatments, which consequently enhances market engagement and funding in ovarian cancer therapies. In 2025, Tilt Biotherapeutics raised €22.6 million ($25.6 million) in Series B funding to advance its oncolytic virus therapy, TILT-123, into a Phase II trial for platinum-resistant ovarian cancer (PROC). The therapy, combined with T cell-based treatments like Merck's Keytruda, showed promising early results, with 64% of patients achieving disease control.

OVARIAN CANCER MARKET GROWTH DRIVERS:

Expansion of Comprehensive Cancer Screening Programs

The expansion of thorough cancer screening initiatives is a major factor influencing the ovarian cancer market. These initiatives focus on identifying cancer during its initial phases, allowing for more successful therapies and better patient results. Through the integration of gender-specific diagnostics, hereditary cancer risk assessment, and tumor markers, these initiatives offer a thorough strategy for cancer detection. As knowledge about the significance of early detection expands, the need for accessible and cost-effective screening options rises, especially in areas with increasing cancer rates. This broader access to screening services not only facilitates earlier intervention but also expands the market for diagnostic tools, driving the demand for innovative products and services in the ovarian cancer space. In 2025, Metropolis Healthcare launched the TruHealth Cancer Screen 360, a comprehensive cancer screening panel aimed at improving early cancer detection in India. The panel includes gender-specific diagnostics, hereditary cancer risk analysis, and tumor markers for multiple cancers. This initiative seeks to address the rising cancer burden, especially in urban and non-urban areas, by making screening more accessible and affordable.

Rise of Genetic Testing and Risk Assessment Initiatives

Enhanced emphasis on identifying individuals with greater genetic susceptibility allows for earlier identification and tailored prevention approaches. This transition towards proactive healthcare enables focused interventions, resulting in better outcomes and possibly lower incidence rates. With genetic testing becoming increasingly available, especially for at-risk individuals and their families, the need for associated diagnostic services, treatments, and educational resources grows. Moreover, these efforts enable patients to make knowledgeable choices regarding their health, ultimately supporting the market growth through heightened awareness and access to early detection tools. In 2024, Stanford Medicine received a $3.5 million legacy gift from Bright Pink to launch the Bright Pink Preventive Risk Outreach and Cascade Testing (PROACT) Program. The initiative aimed to increase genetic testing for breast and ovarian cancer, focusing on at-risk individuals and their families. The program builds on Bright Pink's previous work, making genetic risk assessments more accessible and empowering proactive health management.

Advancements in AI-Driven Cancer Research

The incorporation of artificial intelligence (AI) into ovarian cancer studies is propelling market growth by enhancing early detection, personalized treatment strategies, and accelerating research advancements. AI technologies allow for the examination of large datasets, revealing patterns and insights that were once challenging to discover. Utilizing machine learning (ML) algorithms on patient data enables researchers to create more precise diagnostic tools, enhance treatment protocols, and anticipate patient outcomes. As AI continues to transform research methodologies, it enhances the effectiveness of treatments and improves survival rates, thereby increasing the demand for innovative cancer care solutions and further supporting the market growth. In 2025, the Global Ovarian Cancer Research Consortium launched a $1 million AI Accelerator Grant in partnership with Microsoft's AI for Good Lab. The initiative aims to advance ovarian cancer research by using AI to improve survival rates. The grant will fund multi-country, multidisciplinary research teams to tackle the global ovarian cancer crisis.

OVARIAN CANCER INDUSTRY SEGMENTATION:

Breakup by Type:

• Epithelial Ovarian Cancer
• Germ Cell Ovarian Cancer
• Stromal Cell Ovarian Cancer

Epithelial ovarian cancer represents the leading type

Epithelial ovarian cancer is more commonly diagnosed in older women, and as the global population ages, the incidence of ovarian cancer tends to increase. The risk of developing ovarian cancer rises significantly after menopause, making postmenopausal women more susceptible to this type of cancer. Moreover, obesity and unhealthy lifestyle choices, such as poor diet and lack of physical activity, have been associated with an increased risk of ovarian cancer. The global rise in obesity rates over the past few decades may have contributed to the growing prevalence of epithelial ovarian cancer. Besides, certain genetic mutations, such as BRCA1 and BRCA2 mutations, are known to increase the risk of developing ovarian cancer. Inherited genetic factors can play a significant role in the prevalence of epithelial ovarian cancer, especially in families with a history of the disease.

Breakup by Treatment Type:

• Immunotherapy
• Chemotherapy
• Targeted Therapy
• Surgery
• Others

Immunotherapy is the most popular treatment type

Immunotherapy has emerged as a revolutionary approach in cancer treatment, showing promising results in various cancer types. Ovarian cancer, being one of the deadliest gynecological malignancies, has been a focus of research to identify novel and more effective therapies. Immunotherapy's success in other cancer types has generated significant interest in exploring its potential benefits in ovarian cancer treatment. Moreover, immunotherapy focuses on targeting the tumor microenvironment, which includes various immune cells and signaling molecules that support tumor growth and progression. By modulating the immune response, immunotherapy aims to create an inhospitable environment for cancer cells, hindering their growth and spread.

Breakup by End User:

• Hospitals
• Homecare
• Speciality Centre
• Others

Hospitals are the primary healthcare institutions that play a crucial role in the diagnosis, treatment, and management of ovarian cancer. They offer a comprehensive range of medical services, including surgery, chemotherapy, radiation therapy, and supportive care for ovarian cancer patients. Hospitals typically have specialized oncology departments or cancer centers equipped with advanced medical technology and a multidisciplinary team of healthcare professionals, including oncologists, surgeons, nurses, and support staff.

Homecare services may include nursing care, administration of medications, pain management, wound care, and assistance with activities of daily living. Homecare is particularly beneficial for patients who require ongoing support and monitoring but prefer to receive treatment in a familiar environment. Homecare services aim to enhance the quality of life for ovarian cancer patients, allowing them to remain in their homes while receiving necessary medical attention.

Specialty centers are dedicated healthcare facilities that focus on specific medical conditions or diseases, including ovarian cancer. These centers offer specialized expertise, state-of-the-art facilities, and advanced treatment options tailored to the needs of ovarian cancer patients. Specialty centers include oncology clinics, cancer institutes, and women's health centers that provide comprehensive care, support, and access to cutting-edge therapies and clinical trials for ovarian cancer.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a well-established and technologically advanced healthcare infrastructure, with a high concentration of hospitals, specialty centers, and cancer institutes equipped with state-of-the-art medical facilities and cutting-edge technologies. This enables efficient diagnosis, treatment, and follow-up care for ovarian cancer patients. Moreover, the region is a hub for biomedical research and development, with numerous pharmaceutical and biotechnology companies conducting extensive research on cancer therapies, including ovarian cancer. Ongoing research and clinical trials contribute to the development of innovative treatment options and novel drugs, making North America a frontrunner in ovarian cancer treatment advancements.

COMPETITIVE LANDSCAPE:

The competitive landscape of the ovarian cancer market is characterized by a mix of pharmaceutical companies, biotechnology firms, and academic institutions actively engaged in research, development, and commercialization of treatments and therapies. These companies are developing and commercializing chemotherapy drugs, targeted therapies, and immunotherapies for ovarian cancer treatment. They are also focusing on novel drug development and personalized treatment options. Moreover, various companies are identifying new drug targets, exploring combination therapies, and conducting clinical trials to assess the safety and efficacy of their investigational drugs. They are also forming strategic partnerships with academic institutions, research organizations, and other biopharmaceutical firms to access complementary expertise, resources, and technologies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• AbbVie Inc.
• Amneal Pharmaceuticals Inc.
• AstraZeneca plc
• Eli Lilly and Company
• F. Hoffmann-La
• Roche AG
• GSK plc
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the ovarian cancer market?

2. What is the future outlook of the ovarian cancer market?

3. What are the key factors driving the ovarian cancer market?

4. Which region accounts for the largest ovarian cancer market share?

5. Which are the leading companies in the global ovarian cancer market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Ovarian Cancer Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Epithelial Ovarian Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Germ Cell Ovarian Cancer
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Stromal Cell Ovarian Cancer
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

• 7.1 Immunotherapy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Chemotherapy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Targeted Therapy
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Surgery
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Homecare
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Speciality Centre
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AbbVie Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Amneal Pharmaceuticals Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 AstraZeneca plc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Eli Lilly and Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 F. Hoffmann-La Roche AG
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 GSK plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Hikma Pharmaceuticals PLC
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Lupin Limited
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Pfizer Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Teva Pharmaceutical Industries Ltd.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis